Search Clinical Trials in the European Union

Duration
Visits
Phase
Oral
Benefits
Drugs
Locations
Clinical Specialty
441-460 of 1,694 trials

Cerebral Amyloid Angiopathy: New Treatment Approaches

We are studying whether non-invasive vagus nerve stimulation and low-sodium oxybate can help clear amyloid-beta from the brain in patients with cerebral amyloid angiopathy. This research aims to improve understanding of potential treatments for this condition.

Cerebral Amyloid Angiopathy≤3 monthsEfficacy phase (II)≤5 visitsNo PlaceboStandard MedicinesInternal MedicineNeurology

Achondroplasia: Infigratinib for Children

We are investigating a new medication, infigratinib, for children aged 3 to under 18 with achondroplasia. The study aims to see if it helps improve growth and body proportions while ensuring safety.

Achondroplasia>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesOrthopedics and TraumatologyPediatrics

Juvenile Idiopathic Arthritis: Baricitinib Study

We are investigating whether the medication baricitinib is safe and effective for children and teens aged 1 to 17 with juvenile idiopathic arthritis. This study aims to improve treatment options for this condition.

Juvenile Idiopathic Arthritis>2 yearsConfirmation phase (III)>20 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemotePediatricsRheumatology

Heart Failure: Trimetazidine Study

We are investigating how trimetazidine affects heart function and health markers in people with heart failure. The goal is to see if it can improve symptoms and reduce hospital visits.

Heart Failure with Preserved Ejection Fraction1-2 yearsMonitoring phase (IV)Standard MedicinesCardiologyInternal Medicine

Atopic Dermatitis: Personalized Treatment Approaches

We are studying how genetic and biochemical markers can help choose the best treatment for patients with atopic dermatitis needing stronger therapies. This research may lead to better management strategies tailored to individual needs.

Atopic Dermatitis6-12 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyDermatology

GHB Use Disorder: Baclofen Treatment Study

We are testing whether adding baclofen can help reduce the need for GHB during detox for patients with GHB use disorder. This study aims to improve the detox process for those seeking recovery.

GHB Use DisorderEfficacy phase (II)No PlaceboStandard MedicinesPsychiatry

Colorectal Liver Metastases: HAIP-SYST Treatment Study

We are investigating a new combination of local and systemic chemotherapy for patients with initially unresectable colorectal liver metastases. The study aims to see if this approach improves survival and quality of life compared to standard treatment.

Colorectal Liver Metastases1-2 yearsConfirmation phase (III)No PlaceboInvestigational MedicinesHepatologyOncology

Methylphenidate for Children with KBG Syndrome

We are studying how well methylphenidate helps children and adolescents with KBG syndrome manage attention and emotional symptoms. This trial also looks at family functioning and any side effects compared to typical ADHD treatments.

KBG Syndrome3-6 monthsMonitoring phase (IV)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemotePediatricsPsychiatry

Diffuse Large B-cell Lymphoma: Rituximab and Golcadomide Study

We are testing a new combination treatment for older frail patients with Diffuse Large B-cell non-Hodgkin Lymphoma. This study aims to see if it can improve outcomes without traditional chemotherapy.

Diffuse Large B-cell Lymphoma>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesHematologyInternal Medicine

Heart Failure: Colchicine Study

We are investigating whether colchicine can improve health status in people with heart failure compared to a placebo. This study aims to see if it helps patients feel better based on specific health questionnaires.

Heart Failure with Preserved Ejection Fraction>2 yearsConfirmation phase (III)≤5 visitsStandard MedicinesCardiologyInternal Medicine

Nicotinamide for OPA1 Dominant Optic Atrophy

We are studying whether nicotinamide (vitamin B3) is safe and effective for people with OPA1 Dominant Optic Atrophy. The trial will assess its impact on vision and overall quality of life.

Dominant Optic Atrophy>2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementNeurologyOphthalmology

Cytomegalovirus Treatment: Letermovir and Valganciclovir Combination

We are studying whether a combination of letermovir and valganciclovir helps kidney transplant recipients with CMV infections achieve better viral response than valganciclovir alone.

Cytomegalovirus InfectionKidney Transplant>2 yearsConfirmation phase (III)11-15 visitsInvestigational MedicinesInfectious DiseasesNephrology

Recurrent Diverticulitis: MBK-01 Capsules

We are studying whether MBK-01, a new intestinal microbiota capsule, can help reduce episodes of recurrent diverticulitis. The trial will also assess its safety and find the best dosage for patients.

Acute Diverticulitis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesGastroenterology

Advanced Solid Tumors: Testing IPN01194

We are studying a new drug, IPN01194, for adults with advanced solid tumors to see how safe it is and how well it works. This trial aims to understand its effects when used alone.

MelanomaPancreatic Ductal AdenocarcinomaColorectal Cancer≤3 monthsSafety phase (I)Efficacy phase (II)No PlaceboCost ReimbursementOncology

Becker Muscular Dystrophy: EDG-5506 Treatment Study

We are examining the long-term safety and tolerability of EDG-5506 in adults and adolescents with Becker Muscular Dystrophy. This study aims to understand how well the treatment is tolerated over time.

Becker's Muscular Dystrophy>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementInternal MedicineNeurology

Clostridioides difficile Infection: EXL01 Treatment

We are studying a new oral treatment, EXL01, to see if it can help prevent the return of Clostridioides difficile infection in high-risk patients. The trial will evaluate its safety and effectiveness, along with its impact on digestive health and quality of life.

Recurrent Clostridioides difficile Infection>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesGastroenterologyInfectious Diseases

Limited-Stage Small-Cell Lung Cancer: Tarlatamab Study

We are studying whether tarlatamab can improve survival and prevent disease progression in patients with limited-stage small-cell lung cancer after chemoradiation therapy. Participants will receive either tarlatamab or a placebo to compare their effects.

Limited-Stage Small-Cell Lung CancerConfirmation phase (III)Investigational MedicinesCost ReimbursementOncology

Talquetamab: Reducing Oral Side Effects

We are testing ways to lessen taste changes caused by talquetamab in patients undergoing treatment. The goal is to find effective methods to improve the experience for those affected.

Multiple Myeloma>2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteInternal MedicineOncology

Heart Failure: Optimizing Drug Levels

We are studying how blood levels of heart failure medications affect patient health. This research may help improve treatment plans for individuals with heart failure.

Chronic Heart Failure with Reduced Ejection Fraction>2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal Medicine

MK-5684 Therapies for Advanced Prostate Cancer

We are studying the safety and effectiveness of MK-5684-based treatments for men with metastatic castration-resistant prostate cancer. This research aims to find better options for managing this advanced stage of cancer.

Metastatic Castration-Resistant Prostate Cancer>2 yearsSafety phase (I)Efficacy phase (II)Standard MedicinesCost ReimbursementOncologyUrology